Cannabidiol: FDA approved new drug for the Lennox-Gastaut syndrome and Dravet Syndrome: Pharmacotherapeutics review
Aslam Pathan………………………………p.85-89
Cannabidiol: FDA approved new drug for the Lennox-Gastaut syndrome and Dravet Syndrome: Pharmacotherapeutics review
Aslam Pathan………………………………p.85-89
Caplacizumab: First FDA-approved therapy in 2019 for the treatment of adultpatients with acquired thrombotic thrombocytopenic purpura
Feras Almarshad………………………………p.90-93
Stiripentol: New approved drug for the Dravet syndrome: Pharmacotherapeutics review
Aslam Pathan………………………………p.94-98
Gold Standard of Symptomatic treatment in Parkinson disease: Carbidopa / Levodopa
Aslam Pathan, Abdulrahman M. Alshahrani………………………………p.63-68
Possible management of non-motor symptoms of Parkinson’s Disease
Aslam Pathan ,Abdulrahman M. Alshahrani………………………………p.69-76
Alzheimer’s Disease: Pharmacotherapy of subjective cognitive decline
Aslam Pathan, Abdulrahman M. Alshahrani………………………………p.57-62
Alzheimer’s Disease: Pharmacotherapy of noncognitive symptoms
Aslam Pathan, Abdulrahman M. Alshahrani………………………………p.47-50
Comparative study between open & closed dressing in healing of burn wound
Raman Ohray, Mohit Srivastava, Shally Shengar, Veenita Singh………………………………p.51-56
Evaluation of antiasthmatic effect of Curcuma zedoaria rhizomes by using milk induced leukocytosis in mice
Aslam Pathan, Gautam Vadnere, Mamiyil Sabub………………………………p.13-17
Curcuma caesia rhizomes: evaluation of antiasthmatic effect by using clonidine induced mast cell degranulation
Aslam Pathana, Gautam Vadnerea, Mamiyil Sabub………………………………p.07-12